A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic Fibrosis
Status:
Completed
Trial end date:
2017-10-19
Target enrollment:
Participant gender:
Summary
This is a Phase IIa, multi-center, randomized, double-blind, placebo-controlled,
parallel-group study to evaluate 4 different doses of GLPG2222 administered for 4 weeks to
adult subjects with a confirmed diagnosis of CF and homozygous for the F508del Cystic
Fibrosis Transmembrane conductance Regulator (CFTR) mutation.